{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:41:47Z","timestamp":1783654907296,"version":"3.55.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi230985-4\"><jats:title>Importance<\/jats:title><jats:p>Black men have higher incidence and mortality from prostate cancer. Whether precision oncology disparities affect Black men with metastatic castration-resistant prostate cancer (mCRPC) is unknown.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230985-5\"><jats:title>Objective<\/jats:title><jats:p>To compare precision medicine data and outcomes between Black and White men with mCRPC.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230985-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This retrospective cohort study used data collected by the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) consortium, a multi-institutional registry with linked clinicogenomic data, from April 2020 to December 2021. Participants included Black and White patients with mCRPC with molecular data. Data were analyzed from December 2021 to May 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230985-7\"><jats:title>Exposures<\/jats:title><jats:p>Database-reported race and ethnicity.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230985-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was the frequency of actionable molecular data, defined as the presence of mismatch repair deficiency (MMRD) or high microsatellite instability (MSI-H), homologous recombination repair deficiency, or tumor mutational burden of 10 mutations per megabase or greater. Secondary outcomes included the frequency of other alterations, the type and timing of genomic testing performed, and use of targeted therapy. Efficacy outcomes were prostate-specific antigen response rate, site-reported radiographic response, and overall survival.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230985-9\"><jats:title>Results<\/jats:title><jats:p>A total of 962 eligible patients with mCRPC were identified, including 204 Black patients (21.2%; median [IQR] age at diagnosis, 61 [55-67] years; 131 patients [64.2%] with Gleason scores 8-10; 92 patients [45.1%] with de novo metastatic disease) and 758 White patients (78.8%; median [IQR] age, 63 [57-69] years; 445 patients [58.7%] with Gleason scores 8-10; 310 patients [40.9%] with de novo metastatic disease). Median (IQR) follow-up from mCRPC was 26.6 (14.2-44.7) months. Blood-based molecular testing was more common in Black men (111 men [48.7%]) than White men (317 men [36.4%]; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). Rates of actionable alterations were similar between groups (65 Black men [32.8%]; 215 White men [29.1%]; <jats:italic>P<\/jats:italic>\u2009=\u2009.35), but MMRD or MSI-H was more common in Black men (18 men [9.1]) than White men (36 men [4.9%]; <jats:italic>P<\/jats:italic>\u2009=\u2009.04). <jats:italic>PTEN<\/jats:italic> alterations were less frequent in Black men than White men (31 men [15.7%] vs 194 men [26.3%]; <jats:italic>P<\/jats:italic>\u2009=\u2009.003), as were <jats:italic>TMPRSS<\/jats:italic> alterations (14 men [7.1%] vs 155 men [21.0%]; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). No other differences were seen in the 15 most frequently altered genes, including <jats:italic>TP53<\/jats:italic>, <jats:italic>AR<\/jats:italic>, <jats:italic>CDK12<\/jats:italic>, <jats:italic>RB1<\/jats:italic>, and <jats:italic>PIK3CA<\/jats:italic>. Matched targeted therapy was given less frequently in Black men than White men (22 men [33.5%] vs 115 men [53.5%]; <jats:italic>P<\/jats:italic>\u2009=\u2009.008). There were no differences in response to targeted therapy or survival between the two cohorts.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi230985-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This cohort study of men with mCRPC found higher frequency of MMRD or MSI-H and lower frequency of <jats:italic>PTEN<\/jats:italic> and <jats:italic>TMPRSS<\/jats:italic> alterations in Black men compared with White men. Although Black men received targeted therapy less frequently than White men, no differences were observed in clinical outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.34208","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T15:01:26Z","timestamp":1695049286000},"page":"e2334208","source":"Crossref","is-referenced-by-count":16,"title":["Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1001","volume":"6","author":[{"given":"Clara","family":"Hwang","sequence":"first","affiliation":[{"name":"Henry Ford Health, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Henderson","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chun","family":"Chu","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Holland","sequence":"additional","affiliation":[{"name":"Wayne State University School of Medicine, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank C.","family":"Cackowski","sequence":"additional","affiliation":[{"name":"Wayne State University School of Medicine, Detroit, Michigan"},{"name":"Karmanos Cancer Institute, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Pilling","sequence":"additional","affiliation":[{"name":"Henry Ford Health, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Jang","sequence":"additional","affiliation":[{"name":"Tulane University, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana","family":"Rothstein","sequence":"additional","affiliation":[{"name":"Wayne State University School of Medicine, Detroit, Michigan"},{"name":"Karmanos Cancer Institute, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Labriola","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Park","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Ghose","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet A.","family":"Bilen","sequence":"additional","affiliation":[{"name":"Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Mustafa","sequence":"additional","affiliation":[{"name":"Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kilari","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Pierro","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bicky","family":"Thapa","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Tripathi","sequence":"additional","affiliation":[{"name":"University of Oklahoma, Oklahoma City, Oklahoma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Garje","sequence":"additional","affiliation":[{"name":"University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Ravindra","sequence":"additional","affiliation":[{"name":"University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim S.","family":"Koshkin","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Hernandez","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Schweizer","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[{"name":"University of California San Diego, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya B.","family":"Dorff","sequence":"additional","affiliation":[{"name":"City of Hope, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajjai S.","family":"Alva","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro C.","family":"Barata","sequence":"additional","affiliation":[{"name":"Tulane University, New Orleans, Louisiana"},{"name":"University Hospitals Seidman Cancer Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"issue":"2","key":"zoi230985r1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrurol.2015.298","article-title":"Prostate cancer in men of African origin.","volume":"13","author":"McGinley","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"5","key":"zoi230985r2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.prro.2018.04.009","article-title":"Contemporary prostate cancer radiation therapy in the United States: patterns of care and compliance with quality measures.","volume":"8","author":"Lee","year":"2018","journal-title":"Pract Radiat Oncol"},{"issue":"22","key":"zoi230985r3","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1200\/JCO.2007.13.2555","article-title":"Variations in quality of care for men with early-stage prostate cancer.","volume":"26","author":"Spencer","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi230985r4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ajpath.2017.06.019","article-title":"Analysis of tumor biology to advance cancer health disparity research.","volume":"188","author":"Smith","year":"2018","journal-title":"Am J Pathol"},{"issue":"10","key":"zoi230985r5","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1001\/jamaoncol.2021.2755","article-title":"Assessment of prostate cancer treatment among Black and White patients during the COVID-19 pandemic.","volume":"7","author":"Bernstein","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi230985r6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41391-020-0213-7","article-title":"Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.","volume":"23","author":"Sartor","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"zoi230985r7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.18.01279","article-title":"Overall survival of Black and White men with metastatic castration-resistant prostate cancer treated with docetaxel.","volume":"37","author":"Halabi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"18","key":"zoi230985r8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA5009","article-title":"Abi race: a prospective, multicenter study of Black (B) and White (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).","volume":"36","author":"George","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi230985r9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/oncolo\/oyab057","article-title":"Multi-institutional analysis of the clinical and genomic characteristics of Black patients with metastatic hormone-sensitive prostate cancer.","volume":"27","author":"Freeman","year":"2022","journal-title":"Oncologist"},{"issue":"24","key":"zoi230985r10","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer.","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi230985r11","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer.","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"32","key":"zoi230985r12","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration.","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi230985r13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"18","key":"zoi230985r14","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer.","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"zoi230985r15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1200\/PO.19.00346","article-title":"Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations.","volume":"4","author":"Mota","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"zoi230985r16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejca.2020.05.001","article-title":"Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.","volume":"136","author":"van der Doelen","year":"2020","journal-title":"Eur J Cancer"},{"issue":"4","key":"zoi230985r17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade.","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"zoi230985r18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001065","article-title":"Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.","volume":"8","author":"Barata","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"8","key":"zoi230985r19","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jamaoncol.2016.1854","article-title":"Racial\/ethnic disparities in genomic sequencing.","volume":"2","author":"Spratt","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5","key":"zoi230985r20","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.euf.2016.03.010","article-title":"Individual patient data analysis of randomized clinical trials: impact of Black race on castration-resistant prostate cancer outcomes.","volume":"2","author":"Spratt","year":"2016","journal-title":"Eur Urol Focus"},{"issue":"3","key":"zoi230985r21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41391-021-00433-1","article-title":"PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.","volume":"25","author":"Koshkin","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"zoi230985r22","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers.","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7","key":"zoi230985r23","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1158\/0008-5472.CAN-15-1787","article-title":"Mutational landscape of aggressive prostate tumors in African American men.","volume":"76","author":"Lindquist","year":"2016","journal-title":"Cancer Res"},{"issue":"9","key":"zoi230985r24","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1158\/2159-8290.CD-16-0960","article-title":"Exome sequencing of African-American prostate cancer reveals loss-of-function ERF mutations.","volume":"7","author":"Huang","year":"2017","journal-title":"Cancer Discov"},{"issue":"5","key":"zoi230985r25","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.eururo.2016.07.026","article-title":"Prevalence and prognostic significance of PTEN loss in African-American and European-American men undergoing radical prostatectomy.","volume":"71","author":"Tosoian","year":"2017","journal-title":"Eur Urol"},{"issue":"3","key":"zoi230985r26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1042\/CS20160026","article-title":"Prostate cancer, PI3K, PTEN and prognosis.","volume":"131","author":"Wise","year":"2017","journal-title":"Clin Sci (Lond)"},{"issue":"10","key":"zoi230985r27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11934-017-0724-5","article-title":"African-American prostate cancer disparities.","volume":"18","author":"Smith","year":"2017","journal-title":"Curr Urol Rep"},{"issue":"11","key":"zoi230985r28","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1113135","article-title":"Prostate-cancer mortality at 11 years of follow-up.","volume":"366","author":"Schr\u00f6der","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi230985r29","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1200\/JCO.2009.26.2469","article-title":"Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE.","volume":"28","author":"Moses","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi230985r30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1200\/JCO.2022.40.6_suppl.270","article-title":"Genomic instability is enriched in localized prostate cancers from men of African ancestry.","volume":"40","author":"Nauseef","year":"2022","journal-title":"J Clin Oncol"},{"key":"zoi230985r31","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1200\/PO.19.00399","article-title":"CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-Ribose) polymerase inhibitors, and PD-1 inhibitors.","volume":"4","author":"Antonarakis","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"zoi230985r32","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1200\/PO.19.00383","article-title":"CDK12-mutated prostate cancer: clinical outcomes with standard therapies and immune checkpoint blockade.","volume":"4","author":"Schweizer","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"21","key":"zoi230985r33","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1038\/s41388-020-1280-x","article-title":"Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians.","volume":"39","author":"Yadav","year":"2020","journal-title":"Oncogene"},{"issue":"11","key":"zoi230985r34","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMc2000069","article-title":"Racial differences in genomic profiling of prostate cancer.","volume":"383","author":"Mahal","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"zoi230985r35","doi-asserted-by":"publisher","first-page":"6736","DOI":"10.1158\/0008-5472.CAN-18-0254","article-title":"Whole-genome sequencing reveals elevated tumor mutational burden and initiating driver mutations in African men with treatment-na\u00efve, high-risk prostate cancer.","volume":"78","author":"Jaratlerdsiri","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"zoi230985r36","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s42003-021-02140-y","article-title":"Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences.","volume":"4","author":"Rayford","year":"2021","journal-title":"Commun Biol"},{"issue":"6","key":"zoi230985r37","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1200\/JCO.2017.35.6_suppl.192","article-title":"Survival outcomes for African-American (AA) vs matched Caucasian (CAU) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (sip-T).","volume":"35","author":"Quinn","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi230985r38","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/JU.0000000000000524","article-title":"Racial discrepancies in overall survival among men treated with 223radium.","volume":"203","author":"Zhao","year":"2020","journal-title":"J Urol"},{"issue":"1","key":"zoi230985r39","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41598-018-37128-y","article-title":"Measuring tumor mutational burden (TMB) in plasma from mCRPC patients using two commercial NGS assays.","volume":"9","author":"Qiu","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"zoi230985r40","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1097\/01.ju.0000118907.64125.e0","article-title":"Racial\/ethnic disparities in the treatment of localized\/regional prostate cancer.","volume":"171","author":"Underwood","year":"2004","journal-title":"J Urol"},{"issue":"3","key":"zoi230985r41","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.eururo.2017.07.023","article-title":"Racial disparity in delivering definitive therapy for intermediate\/high-risk localized prostate cancer: the impact of facility features and socioeconomic characteristics.","volume":"73","author":"Friedlander","year":"2018","journal-title":"Eur Urol"},{"issue":"9","key":"zoi230985r42","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/GIM.0b013e3181ab22aa","article-title":"Barriers to the use of genetic testing: a study of racial and ethnic disparities.","volume":"11","author":"Suther","year":"2009","journal-title":"Genet Med"},{"key":"zoi230985r43","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.5213\/inj.1632722.361","article-title":"Racial differences in the diagnosis and treatment of prostate cancer.","volume":"20","author":"Pietro","year":"2016","journal-title":"Int Neurourol J"},{"issue":"5","key":"zoi230985r44","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/j.amepre.2018.05.028","article-title":"Attitudes toward genomic testing and prostate cancer research among Black men.","volume":"55","author":"Rogers","year":"2018","journal-title":"Am J Prev Med"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2809637\/hwang_2023_oi_230985_1694192904.78945.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T15:01:29Z","timestamp":1695049289000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2809637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.34208","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]}}}